Celon Labs launches Amphotericin B Emulsion for Black Fungus treatment

Celon Laboratories (Celon Labs) has launched Amphotericin B Emulsion, an emulsion-based drug for the treatment of Mucormycosis or Black Fungus, which has been increasingly seen in Covid-19 patients during the ongoing second wave in India.

The Hyderabad-based specialty biopharma company said that its Black Fungus drug will be available in the market from next week onwards. The company did not reveal the cost of its Black Fungus medicine.

Nagesh Kumar – Celon Laboratories MD said: “The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying to the domestic market soon.”

Celon Laboratories launches Amphotericin B Emulsion for Black Fungus treatment. Image courtesy of visuals3Dde from Pixabay.

Since 2013, Celon Laboratories had been manufacturing Liposomal Amphotericin B, however, current market demands are not being met because of the lack of availability of lipids, which are critical ingredients imported from Germany.

To address the challenge, Celon Laboratories is said to have developed the alternative emulsion-based formulation.

Amphotericin B Emulsion as the name suggests uses Amphotericin B as a bulk drug apart from containing soybean oil, glycerin, and egg lecithin.

Celon Laboratories said that its in-house research and development team had developed the alternative Black Fungus drug in just three weeks.

The Indian specialty biopharma company said that it will produce 10,000 vials per day, which will cover the Black Fungus treatment of nearly 6,000 patients monthly.